lupus nephritis
Advertisement
Richard Furie discusses new data from BLISS-LN supporting the efficacy and safety of belimumab for active proliferative LN.
In the phase 3 REGENCY trial, adding obinutuzumab to standard therapy for lupus nephritis led to better renal outcomes.
This Freely Filtered episode discusses REGENCY, examining the efficacy and safety of obinutuzumab in active lupus nephritis.
Researchers studied osteoporosis prevalence and risk factors in Chinese patients with lupus nephritis.
The American College of Rheumatology issued a summary of a new guideline for lupus nephritis.
The Lupus Foundation of America will honor Brad H. Rovin, MD, and Alí Duarte-García, MD, at the Evelyn V. Hess Reception.
Lupkynis for lupus nephritis is the focus of six accepted abstracts at the American Society of Nephrology Kidney Week 2024.
A patient may have normal creatinine and complements but still have highly active lupus nephritis requiring therapy.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.